Physician profile
Stephen E Parks
NPI 1154387140
$2,885.17
in general payments reported to CMS, 2019-2025
21 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $77.85 · 2021: $567 · 2022: $409 · 2023: $124 · 2024: $262 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $493.14 | 2019-2024 | Injectafer |
| Glaxosmithkline, LLC. | $469.93 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $465.46 | 2019-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $378.50 | 2021-2025 | Monoferric |
| Argenx US, INC. | $234.91 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $143.52 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $120.72 | 2022 | |
| Merck Sharp & Dohme LLC | $116.40 | 2019 | |
| Sun Pharmaceutical Industries INC. | $114.72 | 2022 | |
| Horizon Therapeutics Plc | $56.38 | 2020-2022 | |
| Genentech USA, INC. | $48.69 | 2019-2025 | Ocrevus Zunovo |
| Biogen, INC. | $46.82 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.43 | 2019-2023 | |
| Ucb, INC. | $27.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.67 | 2022 | |
| Octapharma USA, INC. | $21.12 | 2025 | Octagam Immune Globulin (Human) |
| Ultragenyx Pharmaceutical INC. | $18.51 | 2019 | |
| Janssen Biotech, INC. | $16.67 | 2019 | |
| Amgen INC. | $16.14 | 2024 | Tavneos |
| Organon LLC | $11.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.